Cambridge Healthtech Institute’s Inaugural

Drug Discovery Technologies

Enabling Disruptive Innovation

June 3-4, 2020

High costs and long timelines in biopharma R&D emphasize the need for novel technologies that enable new therapeutic platforms and a better understanding of disease. CHI’s Inaugural Drug Discovery Technologies conference is designed as a comprehensive overview of current and emerging technologies and their providers. Each speaker will address a certain technology and its scientific implications in drug discovery and development programs.  


Coverage will include, but is not limited to:

  • Target ID technologies
  • AI/ML and computational tools
  • CRISPR-genome editing
  • Complex cellular assays
  • Histology, pathology, image analysis
  • Synthetic biology
  • RNAi cell lines
  • Human biospecimen and biobanking
  • Immune profiling and immune monitoring
  • iPS cells for disease modeling
  • In vivo and in vitro pharmacology
  • Discovery pharmacokinetics
  • Preclinical scanners and microscopy
  • Multiplexed error-robust fluorescence in situ hybridization


If you would like to submit a proposal to give a presentation at this meeting, please click here.



All proposals are subject to review by session chairpersons and/or the Scientific Advisory Committee to ensure the overall quality of the conference program. Additionally, as per Cambridge Healthtech Institute’s policy, a select number of vendors and consultants who provide products and services will be offered opportunities for podium presentation slots based on a variety of Corporate Sponsorships.


For more details on the conference, please contact:
Marina Filshtinsky, MD

Executive Director, Conferences

Cambridge Healthtech Institute

Phone: 781-972-5496


For partnering and sponsorship information, please contact:

Companies A-K
Rod Eymael
Manager, Business Development
Phone: 781-247-6286


Companies L-Z
Joseph Vacca, M.S.
Director, Business Development
Phone: 781-972-5431